Villere ST Denis J & Co. LLC Reduces Position in Stryker Corporation $SYK

Villere ST Denis J & Co. LLC decreased its holdings in Stryker Corporation (NYSE:SYK) by 2.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 83,598 shares of the medical technology company’s stock after selling 1,820 shares during the quarter. Stryker accounts for 3.2% of Villere ST Denis J & Co. LLC’s investment portfolio, making the stock its 9th biggest holding. Villere ST Denis J & Co. LLC’s holdings in Stryker were worth $33,074,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the company. Nuveen LLC bought a new position in shares of Stryker during the 1st quarter worth approximately $558,075,000. Price T Rowe Associates Inc. MD lifted its position in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after buying an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Stryker by 66.7% during the 1st quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock worth $511,152,000 after buying an additional 549,643 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after buying an additional 361,136 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock worth $838,640,000 after buying an additional 261,058 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the topic of several recent analyst reports. Rothschild Redb raised shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Evercore ISI lowered their price target on shares of Stryker from $418.00 to $410.00 and set an “outperform” rating on the stock in a report on Tuesday. BTIG Research reaffirmed a “buy” rating on shares of Stryker in a report on Monday, July 14th. Redburn Partners set a $420.00 price target on shares of Stryker in a report on Thursday, September 18th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a report on Wednesday. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $430.10.

Stryker Stock Down 1.5%

Stryker stock opened at $364.77 on Friday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The firm has a market capitalization of $139.46 billion, a price-to-earnings ratio of 48.31, a P/E/G ratio of 2.67 and a beta of 0.94. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. The firm has a 50 day simple moving average of $380.25 and a 200 day simple moving average of $378.75.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the previous year, the business earned $2.81 EPS. Stryker’s revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, analysts predict that Stryker Corporation will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s payout ratio is currently 44.50%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director directly owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. The trade was a 5.84% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.